Artiva Biotherapeutics, Inc. ARTV
At closeNov 6, 2026, 5:49 PM EST
After hours · Nov 6, 5:49 PM ET
- YTD
- -3.26%
- 1 year
- +20.64%
- Market cap
- 202.89M
- Revenue (ttm)
- 2.60M
- EPS (ttm)
- -3.23
- Shares out
- 24.29M
- Forward P/E
- -3.18
- YTD return
- -3.26%
- 1-year return
- +20.64%
- Volume
- 908.72K
- Avg volume
- 651.39K
- Open
- 4.16
- Previous close
- 4.13
- Day's range
- 4.13 – 4.24
- 52-week range
- 3.07 – 13.39
- Price target
- 21.25 (+412.0%)
- Earnings date
- Feb 11, 2025
1D +0.02 (+0.48%)
Key statistics
- Enterprise value
- 138.19M
- PEG ratio
- 0.00
- Price / sales
- 102.35
- Price / book
- 1.32
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 146.63M
- Total debt
- 14.97M
- Return on equity
- 0.00%
- Short % of float
- 4.27%
- 50-day average
- 11.60
- 200-day average
- 11.88
Analyst view
- Target (low)
- 18.00
- Target (mean)
- 21.25
- Target (high)
- 23.00
- Strong buy1
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 11, 2025
Expected Feb 11, 2025. Consensus EPS estimate -0.58.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 11, 2025 | Dec 1, 2024 | -0.71 | — | — | — |
| Nov 12, 2024 | Sep 1, 2024 | -0.68 | -0.92 | -0.24 | -35.29% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 13, 2024 | Needham | reit | Buy | Buy |
| Aug 30, 2024 | Needham | reit | Buy | Buy |
| Aug 13, 2024 | Needham | init | — | Buy |
| Aug 13, 2024 | Wedbush | init | — | Outperform |
| Aug 13, 2024 | Cantor Fitzgerald | init | — | Overweight |
| Aug 13, 2024 | TD Cowen | init | — | Buy |
About Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- artivabio.com
News
Deal Dispatch: DoorDash Buys Instacart For $17B, Thrive Holdings Acquires ADT, SalesForce Nabs Rune Technologies 
Artiva Biotherapeutics Plunges Into Crisis Over Patient Deaths and Possible Liquidation 
12 Health Care Stocks Moving In Tuesday's Intraday Session 
Crude Oil Moves Lower; Corning Earnings Top Views 
Wedbush Downgrades Artiva Biotherapeutics to Neutral, Lowers Price Target to $4 
12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
Artiva Biotherapeutics Cancels ACR Convergence 2026 Data Presentation And November 9 Investor Webcast Following AlloNK Development Discontinuation 
Artiva Biotherapeutics To Reduce Workforce By ~94% Following Discontinuation Of AlloNK Development 
Artiva Biotherapeutics Halts Further Development Of AlloNK Following Fatal Safety Events And FDA-Requested Enrollment Pause 
12 Health Care Stocks Moving In Thursday's After-Market Session
Your note
Sign in to keep a note on ARTV — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| 5AM PARTNERS VI, LLC | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jul 21, 2024 | 0 |
| BUSH JENNIFER KINSBRUNER | Chief Operating Officer | Stock Award(Grant) | Sep 11, 2024 | 72,799 |
| GRAEF THORSTEN | Officer | Stock Award(Grant) | Sep 11, 2024 | 20,000 |
| HORAN CHRISTOPHER | Officer | Stock Award(Grant) | Sep 11, 2024 | 25,000 |
| HUH YONG-JUN | Director | Purchase | Jul 21, 2024 | 0 |
| KRISHNAMOHAN NEHA | Chief Financial Officer | Stock Award(Grant) | Sep 11, 2024 | 50,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, L.P. | 40.57% | 9,853,302 | 107.99M | Sep 29, 2024 |
| 5AM Venture Management, LLC | 9.69% | 2,353,304 | 25.79M | Sep 29, 2024 |
| VR Adviser, LLC | 6.63% | 1,609,569 | 17.64M | Sep 29, 2024 |
| venBio Partners LLC | 6.26% | 1,519,971 | 16.66M | Sep 29, 2024 |
| Capital World Investors | 3.77% | 915,386 | 10.03M | Sep 29, 2024 |
| Vanguard Group Inc | 3.46% | 841,005 | 9.22M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Smallcap World Fund | 3.17% | 770,297 | 8.44M | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 2.22% | 540,173 | 5.92M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.22% | 295,208 | 3.24M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.80% | 193,140 | 2.12M | Sep 29, 2024 |
| Franklin Strategic Series-Franklin Biotechnology Discove | 0.79% | 192,871 | 2.11M | Jul 30, 2024 |
| Fidelity Extended Market Index Fund | 0.33% | 80,188 | 878.86K | Oct 30, 2024 |